Abbonarsi

Periodontal infections cause changes in traditional and novel cardiovascular risk factors: Results from a randomized controlled clinical trial - 17/08/11

Doi : 10.1016/j.ahj.2005.06.018 
Francesco D'Aiuto, DMD, PhD a, Mohamed Parkar, BSc, MPhil a, Luigi Nibali, DMD a, Jean Suvan, RDH, MSc a, Jan Lessem, MD a, Maurizio S. Tonetti, DMD, PhD a, b,
a Department of Periodontology and Eastman Clinical Investigation Centre, University College London (UCL), London, United Kingdom 
b Division of Periodontology, Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center, Farmington, CT 

Reprint requests: Maurizio S. Toretti, Division of Periodontology, Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030.

Riassunto

Background

Chronic infections, such as periodontitis, are associated with increased risk of systemic diseases driven by a persistent low-grade systemic inflammation and metabolic changes. Severity of periodontitis has also been associated with increased systolic blood pressure (BP). However, the issue remains poorly investigated. We aimed to estimate the effect of periodontal therapy on traditional and novel cardiovascular risk factors in systemically healthy individuals who have periodontitis.

Methods

We enrolled 40 otherwise healthy patients with severe chronic generalized periodontitis in a 6-month pilot intervention trial. Individuals were randomized either to a standard course of periodontal therapy (subgingival scaling and root planing) or an intensive one (including the adjunctive use of a locally delivered antimicrobial, IPT).

Results

Compared to control, IPT produced significant reductions in a cluster of inflammatory markers at 1 (P = .0406) and 2 (P = .0060) months together with an improvement in lipid markers at 2 (P = .0320) and 6 (P = .0432) months after therapy. Intensive periodontal therapy produced greater reductions in IL-6 at 1 (0.4 ± 0.2 ng/L difference, 95% CI 0.03-0.9, P = .0284) and 2 months (0.3 ± 0.2 ng/L difference, 95% CI 0.1-0.8, P = .0284), together with decreases in C-reactive protein (0.4 ± 0.2 mg/L difference, 95% CI 0.01-0.8, P = .0438) and total cholesterol (0.3 ± 0.1 mmol/L difference, 95% CI 0.04-0.6, P = .0254). Moreover, a 7 ± 3-mm Hg decrease in systolic BP was observed at 2 months in the IPT group (95% CI 1-12, P = .0211), and this difference was greater in current smokers (14 ± 5 mm Hg 95% CI 3-25, P = 0.0124). Intensive periodontal therapy subjects exhibited a 1.53% ± 1.20% (95% CI 1.05-2.24, P = .0290) and 2.00% ± 1.42% (95% CI 0.98-4.09, P = .0568) decreases in cardiovascular risk scores (Framingham) at 2 and 6 months, respectively, when compared to those in the standard group.

Conclusions

Our findings suggest that intensive periodontal treatment reduces systemic inflammatory markers and systolic BP, and improves lipid profiles with subsequent changes in cardiovascular risk when compared to standard therapy.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 This study was supported by a donation from Orapharma and by the Periodontal Research Fund of the Eastman Dental Institute. The sponsors of the study had a role in study design, but not in data collection, data analysis, data interpretation, or in the writing of the report. F.D. and L.N. are supported by a fellowship from the Italian Society of Periodontology and the European Union.


© 2006  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 151 - N° 5

P. 977-984 - Maggio 2006 Ritorno al numero
Articolo precedente Articolo precedente
  • Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers
  • Juhana Karha, Vivek Rajagopal, Kandice Kottke-Marchant, Deepak L. Bhatt
| Articolo seguente Articolo seguente
  • Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial
  • John J.V. McMurray, James B. Young, Mark E. Dunlap, Christopher B. Granger, James Hainer, Eric L. Michelson, Steven Earle, Bertil Olofsson, Jan Östergren, Salim Yusuf, Karl Swedberg, Marc A. Pfeffer, on behalf of the CHARM Investigators

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.